Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
December 2022
-
Media ReleaseNovartis presents pivotal Phase III APPLY-PNH data at ASH demonstrating investigational oral monotherapy iptacopan superiority over anti-C5Trial met both primary and most secondary endpoints, showing iptacopan provided transfusion-free hemoglobin-level increases in vast majority of adult paroxysmal nocturnal hemoglobinuria (PNH)…
-
Media ReleaseNovartis receives European Commission approval for Pluvicto® as the first targeted radioligand therapy for treatment of progressive PSMA–positive metastatic castration-resistant prostate cancerEC approval based on results from pivotal Phase III VISION trial, in which Pluvicto® plus best standard of care (BSoC) significantly improved overall survival and radiographic progression-free…
-
Media ReleaseNovartis investigational iptacopan provides clinically meaningful increases in hemoglobin levels in complement-inhibitor-naïve patients with PNHPhase III APPOINT-PNH study of investigational oral monotherapy iptacopan met its primary endpoint; second positive Phase III topline readout for iptacopan in paroxysmal nocturnal hemoglobinuria (PNH…
-
Media ReleaseNovartis Kisqali® prolonged PFS benefit for pre- and perimenopausal patients with aggressive HR+/HER2− metastatic breast cancer compared to chemotherapyRIGHT Choice Phase II trial is the first randomized study in patients with aggressive HR+/HER2− metastatic breast cancer (MBC), including visceral crisis, comparing a CDK4/6 inhibitor (CDK4/6i) plus…
-
Media ReleaseNovartis Pluvicto™ shows statistically significant and clinically meaningful radiographic progression-free survival benefit in patients with PSMA–positive metastatic castration-resistant prostate cancerAd hoc announcement pursuant to Art. 53 LR Phase III PSMAfore trial with PluvictoTM met the primary endpoint of radiographic progression-free survival (rPFS) in PSMA–positive mCRPC who have been…
November 2022
-
Featured NewsCreating positive social change through volunteering -
Media ReleaseNovartis and Medicines for Malaria Venture announce decision to move to Phase 3 study for novel ganaplacide/lumefantrine-SDF combination in adults and children with malariaNovartis and Medicines for Malaria Venture (MMV) announce decision to move to Phase 3 study for novel non-artemisinin combination to treat uncomplicated malariaThis novel combination also contains an…
-
Media ReleaseNovartis highlights scientific advances with Kisqali, iptacopan, Scemblix and YTB323 data at SABCS and ASHFirst data to be presented as a late-breaker abstract from global pivotal APPLY-PNH trial of investigational oral monotherapy iptacopan in paroxysmal nocturnal hemoglobinaria (PNH), a rare and…
-
Story
Prostate cancer and support of the care partner – Carl and Arlene’s story -
Media ReleaseNew long-term Leqvio® (inclisiran) data from Novartis show sustained efficacy and safety over four yearsResults from ORION-3 open-label trial show twice-yearly* Leqvio®(inclisiran), as a complement to statin therapy, provides effective and sustained reductions in low-density lipoprotein cholesterol (…
-
Media ReleaseSandoz announces further investment in key manufacturing facility in Austria, to support increased global demand for essential antibioticsEUR 50m planned investment to support increased manufacturing capacity for finished dosage form penicillins, the leading class of antibiotics worldwideNew project brings total planned investment into…
-
Story People and Culture
A scientist from the start – Q&A with NIBR President Fiona Marshall